Mark Weinstein, MD
Allergy & Immunology · Belleville, NJNPI 1528274040
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $78,558 of the $88,282 with a category attached, or 89.0%. 37 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 43.0% of the total. Among allergy & immunology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 600 payments — averaging $147.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$38K
- AbbVie$19K
- Sanofi$14K
- Shire North American Group Inc$10K
- Regeneron Healthcare Solutions, Inc.$1K
- GSK$1K
- plus $5K from 31 others
Across 32 payments — averaging $10,502 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$102K
- Shire North American Group Inc$77K
- Eli Lilly$74K
- Modernatx, Inc.$43K
- Novartis$28K
- Regeneron$13K
What the payments were for
- Speaking & faculty fees$78,55889%
- Food & beverage$9,60411%
- Education$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 41 | $37,991 |
| AbbVie | 39 | $18,936 |
| Sanofi | 40 | $13,514 |
| Shire North American Group Inc | 12 | $10,113 |
| Regeneron Healthcare Solutions, Inc. | 37 | $1,263 |
| GSK | 90 | $1,189 |
| AstraZeneca | 60 | $996 |
| CSL Behring | 59 | $847 |
| Pfizer | 40 | $529 |
| Amgen(2 entities) | 19 | $299 |
| Pharming Healthcare, Inc. | 18 | $285 |
| Novartis | 13 | $264 |
| Genentech USA, Inc. | 17 | $240 |
| Covis Pharma GmbH | 15 | $222 |
| Kaleo, Inc. | 12 | $168 |
| Octapharma USA, Inc. | 9 | $164 |
| Optinose US, Inc. | 10 | $158 |
| Biocryst US Sales Co., LLC | 9 | $139 |
| Grifols USA, LLC | 8 | $128 |
| Bio Products Laboratory USA, Inc. | 5 | $103 |
| Incyte Corporation | 6 | $102 |
| Alk-abello, Inc | 7 | $102 |
| LEO Pharma Inc. | 5 | $76 |
| Cycle Pharmaceuticals Inc | 4 | $74 |
| Boehringer Ingelheim | 5 | $67 |
| Teva Pharmaceuticals USA, Inc. | 5 | $66 |
| Lilly USA, LLC | 3 | $53 |
| Eyevance Pharmaceuticals LLC | 2 | $32 |
| Greer Laboratories, Inc. | 1 | $27 |
| Johnson & Johnson | 1 | $22 |
| Ionis Pharmaceuticals, Inc. | 1 | $20 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
| Organon | 2 | $18 |
| Biocryst Pharmaceuticals, Inc. | 1 | $15 |
| GC Biopharma USA, Inc. | 1 | $14 |
| Phadia US Inc. | 1 | $13 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$88,282 in reported general payments places this provider in the 90th percentile of 135 allergy & immunology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 83 | $282,619 |
| Dupixent PenDupilumab | 45 | $173,112 |
| RinvoqUpadacitinib | 17 | $118,250 |
| TezspireTezepelumab-Ekko | 14 | $54,520 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $21,004 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $19,411 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $10,819 |
| XhanceFluticasone Propionate | 15 | $8,950 |
| Epinephrine | 24 | $6,374 |
| Azelastine Hcl | 150 | $6,093 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,637 |
| Arnuity ElliptaFluticasone Furoate | 22 | $5,239 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $4,501 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $4,250 |
| Fluticasone Propionate | 162 | $3,665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $18,936 | $118,25017 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,189 | $56,472130 claims |
| AstraZenecaTezspire | $996 | $54,52014 claims |
| Optinose US, Inc.Xhance | $158 | $8,95015 claims |
| Boehringer IngelheimStiolto Respimat | $67 | $4,50112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 135 allergy & immunology providers in New Jersey.
Other allergy & immunology in Belleville
- Ellen SherOcean$1M
- Peter RickettiTrenton$457K
- John KimMedford$339K
- Tina ZeccaLittle Silver$262K
- George BelecanechVoorhees$208K
- Jacqueline RossOcean$131K
- Shirin JadidiMendham$98K
- Joseph GrizzantiHawthorne$79K
- Lisa BariscianoFlorham Park$78K
- Kerry LebengerBerkeley Heights$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.